Skip to main content
. 2020 Sep 16;34(11):1177–1189. doi: 10.1007/s40263-020-00760-2

Table 3.

Percentage of responders in the intention-to-treat (ITT) population

ITT with LOCF population TRZ30 (n = 43) TRZ60 (n = 50) PLB (n = 48) p value
Responder, n (%) 27 (62.8) 27 (54.0) 22 (45.8) 0.428a
Non-responder, n (%) 16 (37.2) 23 (46.0) 26 (54.2)

All investigational groups also received gabapentin as background therapy

LOCF last observation carried forward, PLB placebo, TRZ trazodone

aVariables were compared by the Cochran–Mantel–Haenszel test